TSX Penny Stocks Spotlight: Cannabix Technologies And Two More Compelling Picks

In This Article:

As trade tensions ease with new agreements between the U.S. and its trading partners, including the U.K., and talks set to begin with China, financial markets have shown positive momentum. Amid these developments, investors are increasingly looking at penny stocks for potential growth opportunities in smaller or newer companies. Although the term "penny stocks" may seem outdated, these investments can still offer significant upside when backed by strong financials and sound fundamentals.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Westbridge Renewable Energy (TSXV:WEB)

CA$0.81

CA$81.93M

★★★★★★

NTG Clarity Networks (TSXV:NCI)

CA$2.24

CA$99.44M

★★★★★★

Thor Explorations (TSXV:THX)

CA$0.60

CA$372.57M

★★★★☆☆

Orezone Gold (TSX:ORE)

CA$1.03

CA$542.77M

★★★★★☆

Mandalay Resources (TSX:MND)

CA$4.81

CA$449.65M

★★★★★★

McChip Resources (TSXV:MCS)

CA$0.63

CA$3.6M

★★★★☆☆

PetroTal (TSX:TAL)

CA$0.60

CA$539.99M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.63

CA$128.41M

★★★★★★

Findev (TSXV:FDI)

CA$0.45

CA$14.18M

★★★★★★

BluMetric Environmental (TSXV:BLM)

CA$1.30

CA$49.19M

★★★★★★

Click here to see the full list of 902 stocks from our TSX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Cannabix Technologies

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cannabix Technologies Inc. is a technology company that develops marijuana and alcohol breathalyzers for employers, law enforcement, workplaces, and laboratories in the United States, with a market cap of CA$71.39 million.

Operations: Cannabix Technologies Inc. has not reported any specific revenue segments.

Market Cap: CA$71.39M

Cannabix Technologies Inc., with a market cap of CA$71.39 million, is pre-revenue and unprofitable but shows potential through strategic developments. The company recently secured its first international distribution agreement for its BreathLogix alcohol breathalyzers in Australia, New Zealand, and the Pacific Islands. Additionally, it achieved U.S. regulatory approval for its BreathLogix Workplace Series alcohol devices, opening doors to the U.S. market. Despite a negative return on equity and ongoing losses, Cannabix remains debt-free with sufficient cash runway for over a year and has reduced losses by 24.8% annually over five years while maintaining stable volatility.

CNSX:BLO Debt to Equity History and Analysis as at May 2025
CNSX:BLO Debt to Equity History and Analysis as at May 2025

Empress Royalty

Simply Wall St Financial Health Rating: ★★★★☆☆